{"success":true,"data":{"pressRelease":{"id":"88385","rtpr_id":"nGNX34WDQd","ticker":"DBV","exchange":"Euronext Paris","all_tickers":["DBV"],"title":"DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026","author":"Globe Newswire","published_at":"2026-07-14T20:30:00.330Z","article_body":"Châtillon, France, July 14, 2026\n\nDBV Technologies to Report Second Quarter 2026 Financial Results and Business\nUpdate on July 16, 2026\n* Company to host investor conference call and webcast at 5:00 p.m. ET\nDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock\nMarket: DBVT), a late-stage biopharmaceutical company, today announced that\nthe Company will host a conference call and live audio webcast on Thursday,\nJuly 16(th), at 5:00 p.m. ET to review its second quarter 2026 financial\nresults and provide a business update.\n\nInterested participants may access this call via the teleconferencing numbers\nbelow and by asking to join the DBV Technologies Second Quarter 2026 Results\ncall:\n\nUnited States: +1-877-344-8082\n\nInternational: +1-213-992-4618\n\nA live webcast of the call will be available on the Events section of the\nCompany's website here\n(https://www.globenewswire.com/Tracker?data=qQsvKVsAKZb3I_mcqA92b_4Eyma1AG7_ygq1pPW7ovo3XyFOd17WY8Z6KkqjqhPH_e2b3No-CsY9_wP4UKNGTrT2YdRPshND3XYlGempRx1ZLSjs3SLL8k87vs45C-EQ).\n\nAbout DBV Technologies\nDBV Technologies is a late-stage biopharmaceutical company developing\ntreatment options for food allergies and other immunologic conditions with\nsignificant unmet medical need. DBV Technologies is currently focused on\ninvestigating the use of its proprietary VIASKIN(®) patch technology to\naddress food allergies, which are caused by a hypersensitive immune reaction\nand characterized by a range of symptoms varying in severity from mild to\nlife-threatening anaphylaxis. Millions of people live with food allergies,\nincluding young children. Through epicutaneous immunotherapy (EPIT), the\nVIASKIN(®) Patch is designed to introduce microgram amounts of a\nbiologically active compound to the immune system through intact skin. EPIT is\na new class of non-invasive treatment that seeks to modify an individual’s\nunderlying allergy by re-educating the immune system to become desensitized to\nallergen by leveraging the skin’s immune tolerizing properties. DBV\nTechnologies is committed to transforming the care of food allergic people.\nThe Company’s food allergy programs include ongoing clinical trials of the\nVIASKIN(®) Peanut Patch in peanut allergic toddlers (1 through 3 years of\nage) and children (4 through 7 years of age).\n\nDBV Technologies is headquartered in Châtillon, France, with North American\noperations in Warren, NJ. The Company’s ordinary shares are traded on\nsegment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s\nADSs (each representing five ordinary shares) are traded on the Nasdaq Capital\nMarket (DBVT – CUSIP: 23306J309).\n\nFor more information, please visit www.dbvtechnologies.com and engage with\nus on X (formerly Twitter)\n(https://www.globenewswire.com/Tracker?data=ZH5rFm6L2zV0tG8MW92FjgSIryWHTa9SSxf0tr1ly_BoimdPB6GXNKQQkzJsJZLb0LXLa4S6dOONKE-rbLRk4t8Nybvgo7OJXQUQ8Enxn6bimOOLLj2gren_Wzk7pi-0CoKKJbH10EsfMO7GHV-shLV4su60Yi1AqJ6gU5f6UO-pDAO6oHphAbUeWjfIFEKsb6bzlL0uM07ujEIGumKRVzh09e6MLpA50MqZLpf36zSi-aUyKdPloLSqyGXGyWHAffnfbtS5khFbPlsrl2sHa--8fUKI9hep3sT9mKkNuzY=) and LinkedIn\n(https://www.globenewswire.com/Tracker?data=Wac1nu90kQ5nev9Vm0QnSOMphn5sE7jdHxusxfYKKOm3G6xX0nOfW_VGkE_uhdi59X6BH1OWDooeAIvXWDs4LEBPcL_78eMn8cfcphj1bKZNfVFaZJ36e4Esk2NE-CcMycU10895hmVMLRpZx4Fk8hHwkRmZXh6ZFhTIA54QHBczt3j9BlqQHwpbGyB3ZCRGer2_tXq0liYYTonTy8OK1AzHVT1JvVzbGDns90fRloj7olM_fukX2uu6JaBkLP7P2mUicWrl813rIpIfJRyz1fah-gUTuGFIx3J0e7ffMlI=).\n\nVIASKIN is a registered trademark of DBV Technologies.\n\nInvestor Contact \nJonathan Neely\nDBV Technologies\nJonathan.neely@dbv-technologies.com\n\nMedia Contact\nBrett Whelan\nDBV Technologies\nBrett.whelan@dbv-technologies.com\n\nAttachment\n*     PDF Version\n(https://ml-eu.globenewswire.com/Resource/Download/ea281a2f-3e9a-4f35-8c4e-d7fddca51c0b)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/274bd0ae-19c4-4821-85ce-7fe85ee610b5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX34WDQd","title":"DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026","author":"Globe Newswire","ticker":"DBV","created":"2026-07-14T20:30:00.330Z","tickers":["DBV"],"exchange":"Euronext Paris","article_body":"Châtillon, France, July 14, 2026\n\nDBV Technologies to Report Second Quarter 2026 Financial Results and Business\nUpdate on July 16, 2026\n* Company to host investor conference call and webcast at 5:00 p.m. ET\nDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock\nMarket: DBVT), a late-stage biopharmaceutical company, today announced that\nthe Company will host a conference call and live audio webcast on Thursday,\nJuly 16(th), at 5:00 p.m. ET to review its second quarter 2026 financial\nresults and provide a business update.\n\nInterested participants may access this call via the teleconferencing numbers\nbelow and by asking to join the DBV Technologies Second Quarter 2026 Results\ncall:\n\nUnited States: +1-877-344-8082\n\nInternational: +1-213-992-4618\n\nA live webcast of the call will be available on the Events section of the\nCompany's website here\n(https://www.globenewswire.com/Tracker?data=qQsvKVsAKZb3I_mcqA92b_4Eyma1AG7_ygq1pPW7ovo3XyFOd17WY8Z6KkqjqhPH_e2b3No-CsY9_wP4UKNGTrT2YdRPshND3XYlGempRx1ZLSjs3SLL8k87vs45C-EQ).\n\nAbout DBV Technologies\nDBV Technologies is a late-stage biopharmaceutical company developing\ntreatment options for food allergies and other immunologic conditions with\nsignificant unmet medical need. DBV Technologies is currently focused on\ninvestigating the use of its proprietary VIASKIN(®) patch technology to\naddress food allergies, which are caused by a hypersensitive immune reaction\nand characterized by a range of symptoms varying in severity from mild to\nlife-threatening anaphylaxis. Millions of people live with food allergies,\nincluding young children. Through epicutaneous immunotherapy (EPIT), the\nVIASKIN(®) Patch is designed to introduce microgram amounts of a\nbiologically active compound to the immune system through intact skin. EPIT is\na new class of non-invasive treatment that seeks to modify an individual’s\nunderlying allergy by re-educating the immune system to become desensitized to\nallergen by leveraging the skin’s immune tolerizing properties. DBV\nTechnologies is committed to transforming the care of food allergic people.\nThe Company’s food allergy programs include ongoing clinical trials of the\nVIASKIN(®) Peanut Patch in peanut allergic toddlers (1 through 3 years of\nage) and children (4 through 7 years of age).\n\nDBV Technologies is headquartered in Châtillon, France, with North American\noperations in Warren, NJ. The Company’s ordinary shares are traded on\nsegment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s\nADSs (each representing five ordinary shares) are traded on the Nasdaq Capital\nMarket (DBVT – CUSIP: 23306J309).\n\nFor more information, please visit www.dbvtechnologies.com and engage with\nus on X (formerly Twitter)\n(https://www.globenewswire.com/Tracker?data=ZH5rFm6L2zV0tG8MW92FjgSIryWHTa9SSxf0tr1ly_BoimdPB6GXNKQQkzJsJZLb0LXLa4S6dOONKE-rbLRk4t8Nybvgo7OJXQUQ8Enxn6bimOOLLj2gren_Wzk7pi-0CoKKJbH10EsfMO7GHV-shLV4su60Yi1AqJ6gU5f6UO-pDAO6oHphAbUeWjfIFEKsb6bzlL0uM07ujEIGumKRVzh09e6MLpA50MqZLpf36zSi-aUyKdPloLSqyGXGyWHAffnfbtS5khFbPlsrl2sHa--8fUKI9hep3sT9mKkNuzY=) and LinkedIn\n(https://www.globenewswire.com/Tracker?data=Wac1nu90kQ5nev9Vm0QnSOMphn5sE7jdHxusxfYKKOm3G6xX0nOfW_VGkE_uhdi59X6BH1OWDooeAIvXWDs4LEBPcL_78eMn8cfcphj1bKZNfVFaZJ36e4Esk2NE-CcMycU10895hmVMLRpZx4Fk8hHwkRmZXh6ZFhTIA54QHBczt3j9BlqQHwpbGyB3ZCRGer2_tXq0liYYTonTy8OK1AzHVT1JvVzbGDns90fRloj7olM_fukX2uu6JaBkLP7P2mUicWrl813rIpIfJRyz1fah-gUTuGFIx3J0e7ffMlI=).\n\nVIASKIN is a registered trademark of DBV Technologies.\n\nInvestor Contact \nJonathan Neely\nDBV Technologies\nJonathan.neely@dbv-technologies.com\n\nMedia Contact\nBrett Whelan\nDBV Technologies\nBrett.whelan@dbv-technologies.com\n\nAttachment\n*     PDF Version\n(https://ml-eu.globenewswire.com/Resource/Download/ea281a2f-3e9a-4f35-8c4e-d7fddca51c0b)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/274bd0ae-19c4-4821-85ce-7fe85ee610b5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-14T20:30:00.385868632Z","server_sent_at_ms":1784061000385},"received_at":"2026-07-14T20:30:00.446Z","source_url":"https://www.globenewswire.com/news-release/2026/07/14/3327300/0/en/DBV-Technologies-to-Report-Second-Quarter-2026-Financial-Results-and-Business-Update-on-July-16-2026.html"},"analysis":{"id":"77441","press_release_id":"88385","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"DBV Technologies announced it will report its second quarter 2026 financial results on July 16, 2026.\n\nThe company will host a conference call and live audio webcast at 5:00 p.m. ET to review the quarterly results and provide a business update.\n\nDBV is a late-stage biopharmaceutical company focused on developing treatment options for food allergies using its proprietary VIASKIN patch technology.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings calendar entry only; no operational news."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Jonathan Neely","role":"Investor Contact"},{"name":"Brett Whelan","role":"Media Contact"}],"products":["VIASKIN","VIASKIN Peanut Patch"],"companies":[{"name":"DBV Technologies","ticker":"DBV"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a standard earnings calendar announcement. No financial results or operational updates were disclosed in the release; it only provides the date and time for the upcoming report."},"tickerRelevance":{"others":[],"primary":"DBV"},"globalImportance":10,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"calendar-announcement"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"DBV Technologies announced it will report its second quarter 2026 financial results on July 16, 2026.\n\nThe company will host a conference call and live audio webcast at 5:00 p.m. ET to review the quarterly results and provide a business update.\n\nDBV is a late-stage biopharmaceutical company focused on developing treatment options for food allergies using its proprietary VIASKIN patch technology.","key_figures":null,"named_entities":{"people":[{"name":"Jonathan Neely","role":"Investor Contact"},{"name":"Brett Whelan","role":"Media Contact"}],"products":["VIASKIN","VIASKIN Peanut Patch"],"companies":[{"name":"DBV Technologies","ticker":"DBV"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-14T21:41:03.485Z","global_importance":10,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"calendar-announcement"}},"durationMs":194261,"modelName":"glm-4.7"}}